16-23608013-C-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024675.4(PALB2):c.3202-1G>A variant causes a splice acceptor, intron change. The variant allele was found at a frequency of 0.000000684 in 1,461,286 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_024675.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics
- Fanconi anemia complementation group NInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 3Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- familial ovarian cancerInheritance: AD Classification: MODERATE Submitted by: ClinGen
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_024675.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PALB2 | NM_024675.4 | MANE Select | c.3202-1G>A | splice_acceptor intron | N/A | NP_078951.2 | |||
| PALB2 | NM_001407296.1 | c.3142-1G>A | splice_acceptor intron | N/A | NP_001394225.1 | ||||
| PALB2 | NM_001407297.1 | c.3130-1G>A | splice_acceptor intron | N/A | NP_001394226.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PALB2 | ENST00000261584.9 | TSL:1 MANE Select | c.3202-1G>A | splice_acceptor intron | N/A | ENSP00000261584.4 | |||
| PALB2 | ENST00000568219.5 | TSL:1 | c.2317-1G>A | splice_acceptor intron | N/A | ENSP00000454703.2 | |||
| PALB2 | ENST00000713773.1 | n.3266G>A | non_coding_transcript_exon | Exon 12 of 13 | ENSP00000519075.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461286Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726980 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial cancer of breast Pathogenic:5
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
This c.3202-1G>A variant has not been observed in our cohort database nor has been detected in the ExAC database. This variant was however reported in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/371966/). This variant is located at the invariant acceptor splice site of intron 11 of the PALB2 gene. While not validated for clinical use, computer-based algorithms predict this c.3202-1G>A change to disrupt the splicing site. This variant is classified as pathogenic
This sequence change affects an acceptor splice site in intron 11 of the PALB2 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PALB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 371966). Studies have shown that disruption of this splice site results in activation of a cryptic splice site, and produces a non-functional protein and/or introduces a premature termination codon (internal data). For these reasons, this variant has been classified as Pathogenic.
not provided Pathogenic:2
The PALB2 c.3202-1G>A variant disrupts a canonical splice-acceptor site and interferes with normal PALB2 mRNA splicing. This variant has been reported in the published literature in an individual with breast cancer (PMID: 34196900 (2021)) and in a cohort of individuals undergoing genetic testing for incidental findings (PMIDs: 31447099 (2019) and 32546831 (2020)). This variant has not been reported in large, multi-ethnic general populations (Genome Aggregation Database, http://gnomad.broadinstitute.org). Based on the available information, this variant is classified as pathogenic.
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.3202-1G>A intronic variant results from a G to A substitution one nucleotide upstream from coding exon 12 of the PALB2 gene. This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration may weaken the native splice acceptor site; however, direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.
PVS1; PM2_SUP, PM5_SUP
Familial cancer of breast;C1835817:Fanconi anemia complementation group N;C3150547:Pancreatic cancer, susceptibility to, 3 Pathogenic:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at